title: Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.
abstract: The incidence of malignant melanoma is rising faster than any other malignancy. Although earlier stage patients can be cured with surgical resection with or without adjuvant therapy, a significant number of patients go on to develop disseminated disease. Currently, limited therapeutic options exist for patients with metastatic melanoma. Recent studies suggest that patient selection is feasible and may enable the restriction of treatment to those most likely to benefit. Additionally, several potential mechanisms of tumor resistance have been identified creating opportunities for circumventing them. This article will review current strategies for patient selection and overcoming therapeutic resistance. These strategies hold the promise of extending the clinical benefits of current therapies as well as facilitating the development of additional and more active treatments.
authors.affiliation: Beth Israel Deaconess Medical Center, Biologic Therapeutics Program, 330 Brookline Avenue, Boston, Massachusetts 02215, USA. hkoon@bidmc.harvard.edu
authors.forename: Henry B
authors.initials: HB
authors.lastname: Koon
authors.forename: Michael B
authors.initials: MB
authors.lastname: Atkins
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D015551:Autoimmunity; D016207:Cytokines / Q000627:therapeutic use; D006801:Humans; D007113:Immunity, Innate; D007167:Immunotherapy; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D009362:Neoplasm Metastasis; D018579:Patient Selection; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016207:Cytokines